PBYIPuma Biotechnology, Inc.

$311M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$55M+5.3% YoY

Gross Profit

$43M78.5% margin

Operating Income

-$24M-42.6% margin

Net Income

$4M7.6% margin

EPS (Diluted)

$0.10

QoQ Revenue Growth

+19.7%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$227M

Total Liabilities

$229M

Stockholders' Equity

-$2M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$55M	$53M	+5.3%
Gross Profit	$43M	$42M	+4.4%
Operating Income	-$24M	-$11M	-111.5%
Net Income	$4M	-$15M	+128.2%

Revenue Segments

Product

$140M72%

License

$49M25%

Royalty

$6M3%

PBYI Q4 2021 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena